LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
July 20, 2023 16:05 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced...
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
July 18, 2023 08:00 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has entered into a securities purchase...
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
July 17, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Results Provide Striking Molecular Evidence that Inhibiting PP2A with LB-100 Sensitizes Cancer Cells to Immunotherapy and Chemotherapy PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE...
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
June 23, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock...
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
June 07, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use...
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
June 02, 2023 12:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced today that it will effect a 1-for-10 reverse stock split of its...
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
May 30, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 ...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
April 24, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
April 04, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal...
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
February 14, 2023 13:50 ET
|
Lixte Biotechnology Holdings, Inc.
THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM ...